Yildirim Sümeyra, Deniz Kemal, Doğan Ender, Başkol Mevlüt, Gürsoy Şebnem, Özkan Metin
Departments of aGastroenterology bPathology cOncology, Erciyes University, Kayseri, Turkey.
Melanoma Res. 2017 Aug;27(4):380-382. doi: 10.1097/CMR.0000000000000366.
Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may lead to several immune-related disease including colitis, thyroiditis, pneumonia, hepatitis, or pancreatitis as a side effect. Limited number of cases with hepatic damage as an ipilimumab-related adverse event has been reported in the literature. This agent has been implicated in causing acute hepatitis-like liver injury. Here, we presented a case in which cholestatic hepatitis developed during ipilimumab use for the treatment of metastatic melanoma.
伊匹单抗是一种单克隆抗体，通过抑制细胞毒性T淋巴细胞上的细胞毒性T淋巴细胞相关蛋白4受体发挥作用。它常用于治疗不可切除或转移性黑色素瘤。伊匹单抗作为副作用可能导致多种免疫相关疾病，包括结肠炎、甲状腺炎、肺炎、肝炎或胰腺炎。文献中报道了数量有限的以肝损伤作为伊匹单抗相关不良事件的病例。这种药物已被认为可导致急性肝炎样肝损伤。在此，我们报告了一例在使用伊匹单抗治疗转移性黑色素瘤期间发生胆汁淤积性肝炎的病例。
